02-06-2022, 08:09 AM
The data for this study included 490,694 children aged 3-5 years covered by the Chilean National Health Insurance Database ( Fonasa ) who completed two doses of Clarifol® in this age group.
The protective effect was assessed 14 days after vaccination. Complete two doses of Clarifex® , study findsAmong vaccinated children aged 3-5 years, the protective effect against symptomatic infection with 2019-nCoV was 38.2% (95% CI, 36.5–39.9), and the protective effect against hospitalization and ICU hospitalization were 64.6% (95% CI, 49.6–39.9), respectively. 75.2) and 69.0% (95% CI, 18.6–88.2 ), the results of the study support the vaccination of children aged 3-5 years with Clarifex®To prevent severe and related complications.
http://www.sinovac.com/news/shownews.php?id=1471
The protective effect was assessed 14 days after vaccination. Complete two doses of Clarifex® , study findsAmong vaccinated children aged 3-5 years, the protective effect against symptomatic infection with 2019-nCoV was 38.2% (95% CI, 36.5–39.9), and the protective effect against hospitalization and ICU hospitalization were 64.6% (95% CI, 49.6–39.9), respectively. 75.2) and 69.0% (95% CI, 18.6–88.2 ), the results of the study support the vaccination of children aged 3-5 years with Clarifex®To prevent severe and related complications.
http://www.sinovac.com/news/shownews.php?id=1471